血球蛋白糖化指数和甘油三糖指数与糖尿病病有关
1Department of Nephrology, Gaziosmanpasa City Hospital, Istanbul, Turkey.
Cirugia y cirujanos
|April 16, 2025
概括
甘油三糖指数 (TGI) 和血红蛋白糖化指数 (HGI) 独立地与2型糖尿病患者的糖尿病脏病 (DN) 相关. 这些标记可能有助于DN评估,特别是在贫血个体.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
- 代谢综合征是代谢综合征的一种.
背景情况:
- 糖尿病病 (DN) 是糖尿病的一个主要并发症,尽管有血糖控制,但往往会进展.
- 禁食血葡萄糖 (FPG) 和HbA1c可能无法完全捕捉血糖变化及其对DN的影响.
- 甘油三指数 (TGI) 和血红蛋白糖化指数 (HGI) 是胰岛素耐药性和血糖变化的新兴生物标志物.
研究的目的:
- 调查TGI和HGI与2型糖尿病患者中DN存在的关联.
- 评估TGI和HGI作为DN的潜在指标的有用性.
- 探索TGI和HGI对DN的独立预测值.
主要方法:
- 对234名2型糖尿病患者的回顾性分析.
- 在患有DN和没有DN的患者之间比较TGI和HGI水平.
- 后勤回归分析,以评估TGI和HGI与微专尿的关联.
主要成果:
- 在234名患者中,有76人患有糖尿病病.
- 与没有DN的患者相比,DN的患者表现出明显更高的TGI和HGI水平.
- 后勤回归证实,TGI (OR=3.35) 和HGI (OR=2.579) 两者都与DN的标志物microalbuminuria独立相关.
结论:
- 在2型糖尿病中,TGI和HGI独立地与糖尿病病有关.
- 这些指数可以作为评估DN风险和进展的有价值工具.
- 这些发现对于贫血患者来说尤其重要,因为HbA1c可能不那么可靠.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Symptoms, Diagnosis, and Complications
483
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
483
Dipeptidyl Peptidase 4 Inhibitors
130
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
130
Hypoglycemia and Glucagon
142
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
142
Oral Hypoglycemic Agents: Glinides
111
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
111
Oral Hypoglycemic Agents: Biguanides and Glitazones
140
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
140


